Korean Real-world Study on MASLD/MASH Outcomes.
← catalyst calendarNCT07739901 · readout in 41 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
10,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-13 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- MASLD/MASH
Intervention
- Other: No treatment is given
Primary outcomes
what the primary-completion date above is the date OFOccurrence of decompensated cirrhosis
measured From index date (second VCTE and start of follow-up) to the first occurrence of major adverse liver outcome (MALO) (up to 31 Dec 2025)
Occurrence of hepatocellular carcinoma (HCC) confirmed by imaging or biopsy
measured From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
Liver transplantation
measured From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
All-cause death
measured From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed